## CARCINOMA OF THE EYELID STAGING FORM

### Clinical Extent of Disease before any treatment

<table>
<thead>
<tr>
<th>Tumor size:</th>
<th>Laterality</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
<td>□Left □Right □Bilateral</td>
</tr>
</tbody>
</table>

### Pathologic Extent of disease through completion of definitive surgery

| □y pathologic staging completed after neoadjuvant therapy AND subsequent surgery |

### PRIMARY TUMOR (T)

<table>
<thead>
<tr>
<th>□</th>
<th>□</th>
<th>□</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>T0</td>
<td>T1</td>
</tr>
<tr>
<td>T1a</td>
<td>T1b</td>
<td>T1c</td>
</tr>
<tr>
<td>T2a</td>
<td>T2b</td>
<td>T3a</td>
</tr>
<tr>
<td>T3b</td>
<td>T4</td>
<td></td>
</tr>
</tbody>
</table>

- Tumor size: _______
- Laterality: □Left □Right □Bilateral

### REGIONAL LYMPH NODES (N)

<table>
<thead>
<tr>
<th>□</th>
<th>□</th>
<th>□</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>N0</td>
<td>N1</td>
</tr>
</tbody>
</table>

- Laterality: □Left □Right □Bilateral

### DISTANT METASTASIS (M)

<table>
<thead>
<tr>
<th>□</th>
<th>□</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>M1</td>
</tr>
</tbody>
</table>

- Laterality: □Left □Right □Bilateral

### ANATOMIC STAGE + PROGNOSTIC GROUPS

<table>
<thead>
<tr>
<th>GROUP</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>I A</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>I B</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>I C</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II</td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>III A</td>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>III B</td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td>III C</td>
<td>T4</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

- Laterality: □Left □Right □Bilateral

- Pathologic:
  - □ | □ | □ |
  - 0 | Tis | N0 | M0 |
- Clinical:
  - □ | □ | □ |
  - 0 | Tis | N0 | M0 |
  - I A | T1 | N0 | M0 |
  - I B | T2a| N0 | M0 |
  - I C | T2b| N0 | M0 |
  - II | T3a| N0 | M0 |
  - III A | T3b| N0 | M0 |
  - III B | Any T | N1 | M0 |
  - III C | T4 | Any N | M0 |
  - IV | Any T | Any N | M1 |

- Laterality: □Left □Right □Bilateral
**Data Form for Cancer Staging**

**CARCINOMA OF THE EYELID STAGING FORM**

**PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)**

**REQUIRED FOR STAGING:** None

**CLINICALLY SIGNIFICANT:**
- Sentinel Lymph Node Biopsy (SLNB) results:
- Regional nodes identified on clinical or radiographic examination:
- Perineural invasion:
- Tumor necrosis:
- Pagetoid spread:
- More than 3 Mohs microscopic surgical layers required:
- Immunosuppression — patient has HIV:
- Immunosuppression — history of solid organ transplant or leukemia:
- Prior radiation to the tumor field:
- Excluding skin cancer, patient has history of two or more carcinomas:
- Patient has Muir-Torre syndrome:
- Patient has xeroderma pigmentosa:

**For Eyelid Cutaneous Squamous Cell Carcinoma only (see cSCC, Chapter 29):**

**REQUIRED FOR STAGING:** Tumor thickness (in mm):

- Clark's Level:
  - Presence / absence of perineural invasion:
  - Primary site location on ear or non-glabrous lip:
  - Histologic grade:
  - Size of largest lymph node metastasis:

**Histologic Grade (G) (also known as overall grade)**

<table>
<thead>
<tr>
<th>Grading system</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 grade system</td>
<td>Grade I or 1</td>
</tr>
<tr>
<td>3 grade system</td>
<td>Grade II or 2</td>
</tr>
<tr>
<td>4 grade system</td>
<td>Grade III or 3</td>
</tr>
<tr>
<td>No 2, 3, or 4 grade system is available</td>
<td>Grade IV or 4</td>
</tr>
</tbody>
</table>

**ADDITIONAL DESCRIPTORS**

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

**Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

**General Notes:**
For identification of special cases of TNM or pTNM classifications, the 'm' suffix and 'y', 'r', and 'a' prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a 'y' prefix.
- T(y)NM or p(y)TNM categorizes the extent of tumor actually present at the time of that examination. The 'y' categorization is not an estimate of tumor prior to multimodality therapy.
- r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the 'r' prefix: rTNM.

- a prefix designates the stage determined at autopsy: aTNM.

Surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.
NAME: ___________________________________  MRN: _________________________________

Data Form for Cancer Staging
CARCINOMA OF THE EYELID STAGING FORM

☐ Clinical stage was used in treatment planning (describe): ________________________________

☐ National guidelines were used in treatment planning  ☐ NCCN  ☐ Other (describe): ________________________________

__________________________________________________________________________________

Physician signature ___________________________  Date/Time ____________________________

Form No: MR0045  American Joint Committee on Cancer 2010
EC App 12/94  Revised EC 05/10  Page 4 of 5
Data Form for Cancer Staging
CARCINOMA OF THE EYELID STAGING FORM

Illustration
Indicate on diagram primary tumor and regional nodes involved.

[Diagram showing anatomical structures of the eyelids and orbit, including lacrimal glands, levator muscles, tarsal plates, lacrimal sac, orbital roof, choroid, ciliary body, iris, uvea, upper eyelid, lower eyelid, and conjunctiva.]